Folgen
prof. Nicola Silvestris - Full Professor in Medical Oncology
prof. Nicola Silvestris - Full Professor in Medical Oncology
Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Italy
Bestätigte E-Mail-Adresse bei unime.it
Titel
Zitiert von
Zitiert von
Jahr
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
G Numico, O Garrone, V Dongiovanni, N Silvestris, I Colantonio, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
2262005
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
1552020
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
M Russano, A Napolitano, G Ribelli, M Iuliani, S Simonetti, F Citarella, ...
Journal of Experimental & Clinical Cancer Research 39 (1), 1-13, 2020
1312020
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
D Santini, M Tampellini, B Vincenzi, T Ibrahim, C Ortega, V Virzi, ...
Annals of oncology 23 (8), 2072-2077, 2012
1302012
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
S Rizzo, G Bronte, D Fanale, L Corsini, N Silvestris, D Santini, G Gulotta, ...
Cancer treatment reviews 36, S56-S61, 2010
1302010
Hospital admission of cancer patients: avoidable practice or necessary care?
G Numico, A Cristofano, A Mozzicafreddo, OE Cursio, P Franco, ...
PloS one 10 (3), e0120827, 2015
1202015
Dasatinib: an anti-tumour agent via Src inhibition
A Gnoni, I Marech, N Silvestris, A Vacca, V Lorusso
Current drug targets 12 (4), 563-578, 2011
1072011
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells
A Azzariti, RM Iacobazzi, R Di Fonte, L Porcelli, R Gristina, P Favia, ...
Scientific reports 9 (1), 1-13, 2019
1042019
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
F De Vita, F Giuliani, N Silvestris, G Catalano, F Ciardiello, M Orditura
Cancer treatment reviews 36, S11-S15, 2010
1022010
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
JS Chu, FJ Ge, B Zhang, Y Wang, N Silvestris, LJ Liu, CH Zhao, L Lin, ...
Journal of Experimental & Clinical Cancer Research 32 (1), 1-8, 2013
982013
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ...
Oncotarget 7 (41), 67142, 2016
942016
Adjuvant colon cancer chemotherapy: where we are and where we'll go
L Lombardi, F Morelli, S Cinieri, D Santini, N Silvestris, N Fazio, L Orlando, ...
Cancer treatment reviews 36, S34-S41, 2010
932010
Immunotherapy for colorectal cancer: where are we heading?
D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ...
Expert opinion on biological therapy 17 (6), 709-721, 2017
922017
Molecularly targeted endocrine therapies for breast cancer
L Orlando, P Schiavone, P Fedele, N Calvani, A Nacci, P Rizzo, A Marino, ...
Cancer treatment reviews 36, S67-S71, 2010
882010
High density of tryptase‐positive mast cells in human colorectal cancer: a poor prognostic factor related to protease‐activated receptor 2 expression
A Malfettone, N Silvestris, C Saponaro, G Ranieri, A Russo, S Caruso, ...
Journal of cellular and molecular medicine 17 (8), 1025-1037, 2013
852013
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
A Gnoni, N Silvestris, A Licchetta, D Santini, M Scartozzi, R Ria, S Pisconti, ...
Critical reviews in oncology/hematology 95 (1), 46-61, 2015
842015
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
V Longo, O Brunetti, A Gnoni, S Cascinu, G Gasparini, V Lorusso, ...
Oncotarget 7 (36), 58649, 2016
832016
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
G Bronte, N Silvestris, M Castiglia, A Galvano, F Passiglia, G Sortino, ...
Oncotarget 6 (28), 24780, 2015
822015
The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer
SF Valilou, M Keshavarz-Fathi, N Silvestris, A Argentiero, N Rezaei
Cytokine & growth factor reviews 39, 46-61, 2018
802018
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions
A Gnoni, A Licchetta, A Scarpa, A Azzariti, AE Brunetti, G Simone, ...
International journal of molecular sciences 14 (10), 19731-19762, 2013
802013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20